Victor Hugo Dos Santos

Pristimerin exhibits significant potential as a therapeutic agent, demonstrating activity against various human cancer cells. The assumption is that the trimer of pristimerin enhances the strength and selectivity of pristimerin-DNA interactions through a multivalent effect. Therefore, to synthesize the trimer of pristimerin, a multi-step route was adopted. The initial step involved the synthesis of 2-(2-(2-azidoetoxy)ethoxy)ethan-1-ol (R1) through an SN2 reaction, with a yield of 52%. The compound N-(tert-butoxyl-carbonyl)-tris-(hydroxymethyl)aminomethane (R2), with the amino group protected by tert-butoxyl carbamate, was obtained with an 87% yield and, the trialkyne, N-(tert-butoxyl-carbonyl)-tris-(propargyl)-methyl)aminomethane (R3), was obtained with a 43% yield. Despite successful synthesis of compound R1, R2 and R3, various methodologies were attempted for the transesterification between pristimerin and R1 to produce 2-(2-(2-azidoethoxy)ethoxyethyl pristimerinoate (R4), including chemical and enzymatic hydrolysis of pristimerin as an alternative route. However, none of these attempts succeeded, indicating the remarkable resistance of carbon C-29 in pristimerin to these reactions. DOI:https://doi.org/10.56238/sevened2024.003-056 Pristimerina apresenta um potencial significativo como agente terapêutico, destacando-se pela sua atividade contra diversas células cancerosas humanas. Supõe-se que o trímero da pristimerina potencialize a força e a seletividade das interações entre a pristimerina e o DNA, por meio de um efeito multivalente. Diante disso, para sintetizar o trímero da pristimerina, foi planejado uma rota sintética com várias etapas. A primeira etapa, envolveu a obtenção do produto 2-(2-(2-azidoetoxi)etoxi)etan-1-ol (R1), via reação SN2, com rendimento de 53%. O composto N-(terc-butoxil-carbonil)-tris-(hidroximetil)aminometano (R2), com o grupo amino protegido com terc-butoxil carbamato foi obtido com rendimento de 87% e o trialcino, N-(terc-butoxil-carbonil)-tris-(propargil)metil)aminometano (R3), com rendimento de 43%. Apesar do êxito nas sínteses dos compostos R1, R2 e R3, foram empregadas diversas metodologias na transesterificação entre a pristimerina e R1 para obtenção do produto pristimerinoato de 2-(2-(2-azidoetoxi)etoxi (R4), incluindo a hidrólise química e enzimática da pristimerina como uma rota alternativa. No entanto, nenhuma das tentativas obteve sucesso, evidenciando a notável resistência do carbono C-29 da pristimerina a essas reações. DOI:https://doi.org/10.56238/sevened2024.003-056

Pristimerin exhibits significant potential as a therapeutic agent, demonstrating activity against various human cancer cells. The assumption is that the trimer of pristimerin enhances the strength and selectivity of pristimerin-DNA interactions through a multivalent effect. Therefore, to synthesize the trimer of pristimerin, a multi-step route was adopted. The initial step involved the synthesis of 2-(2-(2-azidoetoxy)ethoxy)ethan-1-ol (R1) through an SN2 reaction, with a yield of 52%. The compound N-(tert-butoxyl-carbonyl)-tris-(hydroxymethyl)aminomethane (R2), with the amino group protected by tert-butoxyl carbamate, was obtained with an 87% yield and, the trialkyne, N-(tert-butoxyl-carbonyl)-tris-(propargyl)-methyl)aminomethane (R3), was obtained with a 43% yield. Despite successful synthesis of compound R1, R2 and R3, various methodologies were attempted for the transesterification between pristimerin and R1 to produce 2-(2-(2-azidoethoxy)ethoxyethyl pristimerinoate (R4), including chemical and enzymatic hydrolysis of pristimerin as an alternative route. However, none of these attempts succeeded, indicating the remarkable resistance of carbon C-29 in pristimerin to these reactions.